Patent · US Active

Use of mimecan in the assessment of heart failure

US10234462B2 · kind B2 · utility

7Cited by

7References

14Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Dirk Block · Bichl, DE
Sara Arab · Toronto, CA
Georg Hess · Mainz, DE
Hendrik Huedig · Penzberg, DE
Peter Liu · Toronto, CA
Ursula-Henrike Wienhues-Thelen · Krailling, DE

Key dates

Filing date	Jan 26, 2012
Grant date	Mar 19, 2019
Priority date	—
Expiry date	Jan 26, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/325
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.